These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 27472228)

  • 1. First-Line Immune Therapy-Implications for Pathologists.
    Miller RA; Cagle PT; Bernicker EH
    Arch Pathol Lab Med; 2016 Aug; 140(8):739-40. PubMed ID: 27472228
    [No Abstract]   [Full Text] [Related]  

  • 2. Non-Small Cell Lung Cancer, PD-L1, and the Pathologist.
    Kerr KM; Nicolson MC
    Arch Pathol Lab Med; 2016 Mar; 140(3):249-54. PubMed ID: 26927720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A New Immunotherapy Drug Creates a Watershed for the Surgical Pathologist's Role in Patient Care.
    Cagle PT; Bernicker EH
    Arch Pathol Lab Med; 2015 Nov; 139(11):1329. PubMed ID: 26516934
    [No Abstract]   [Full Text] [Related]  

  • 4. PD-1-targeted immunotherapy: recent clinical findings.
    Brahmer JR
    Clin Adv Hematol Oncol; 2012 Oct; 10(10):674-5. PubMed ID: 23187774
    [No Abstract]   [Full Text] [Related]  

  • 5. Challenges to Biomarker Testing for PD-1/PD-L1 Checkpoint Inhibitors for Lung Cancer.
    Cagle PT; Bernicker EH
    Arch Pathol Lab Med; 2015 Dec; 139(12):1477-8. PubMed ID: 26619015
    [No Abstract]   [Full Text] [Related]  

  • 6. Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer.
    He J; Hu Y; Hu M; Li B
    Sci Rep; 2015 Aug; 5():13110. PubMed ID: 26279307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non-Small-Cell Lung Cancer: A Review.
    Sacher AG; Gandhi L
    JAMA Oncol; 2016 Sep; 2(9):1217-22. PubMed ID: 27310809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-PD-1/PD-L1 antibodies in non-small cell lung cancer: the era of immunotherapy.
    Valecha GK; Vennepureddy A; Ibrahim U; Safa F; Samra B; Atallah JP
    Expert Rev Anticancer Ther; 2017 Jan; 17(1):47-59. PubMed ID: 27841044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immuno-oncology drugs jostle for first-line setting.
    Mullard A
    Nat Rev Drug Discov; 2016 Nov; 15(11):738. PubMed ID: 27807351
    [No Abstract]   [Full Text] [Related]  

  • 10. Immune Checkpoint Therapy in Non-Small Cell Lung Cancer.
    Marrone KA; Brahmer JR
    Cancer J; 2016; 22(2):81-91. PubMed ID: 27111902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive biomarkers for programmed death-1/programmed death ligand immune checkpoint inhibitors in nonsmall cell lung cancer.
    Remon J; Chaput N; Planchard D
    Curr Opin Oncol; 2016 Mar; 28(2):122-9. PubMed ID: 26756384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer.
    Garon EB
    Semin Oncol; 2015 Oct; 42 Suppl 2():S11-8. PubMed ID: 26477470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted programmed cell death in lung cancer treatment.
    Zimmerman MP; Mehr SR
    Am J Manag Care; 2014 Mar; 20(5 Spec No.):E3. PubMed ID: 25618630
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical Trials of PD-1 and PD-L1 inhibitors in NSCLC.
    Clin Adv Hematol Oncol; 2014 Jan; 12(1 Suppl 1):14-6. PubMed ID: 24852398
    [No Abstract]   [Full Text] [Related]  

  • 15. Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation.
    Chen N; Fang W; Zhan J; Hong S; Tang Y; Kang S; Zhang Y; He X; Zhou T; Qin T; Huang Y; Yi X; Zhang L
    J Thorac Oncol; 2015 Jun; 10(6):910-23. PubMed ID: 25658629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-L1 expression as a potential predictive biomarker.
    Fusi A; Festino L; Botti G; Masucci G; Melero I; Lorigan P; Ascierto PA
    Lancet Oncol; 2015 Oct; 16(13):1285-7. PubMed ID: 26433815
    [No Abstract]   [Full Text] [Related]  

  • 17. PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer.
    Bagley SJ; Bauml JM; Langer CJ
    Clin Adv Hematol Oncol; 2015 Oct; 13(10):676-83. PubMed ID: 27058572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. American Association of Cancer Research Showcases Immunotherapy Advances.
    Brower V
    J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 26243202
    [No Abstract]   [Full Text] [Related]  

  • 19. Advances in Immuno-Oncology: Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer-Introduction.
    Socinski MA
    Semin Oncol; 2015 Oct; 42 Suppl 2():S1-2. PubMed ID: 26477469
    [No Abstract]   [Full Text] [Related]  

  • 20. Emerging immunotherapies in the treatment of non-small cell lung cancer (NSCLC): the role of immune checkpoint inhibitors.
    Langer CJ
    Am J Clin Oncol; 2015 Aug; 38(4):422-30. PubMed ID: 24685885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.